Tumor Biology

, Volume 37, Issue 2, pp 2171–2176 | Cite as

The R156R ERCC2 polymorphism as a risk factor of endometrial cancer

  • Magdalena M. Michalska
  • Dariusz Samulak
  • Filip Jabłoński
  • Hanna Romanowicz
  • Beata Smolarz
Original Article
  • 127 Downloads

Abstract

Endometrial carcinoma (EC) is the most frequent malignant neoplasm of female genitals and the fourth most frequent malignant neoplasm in Polish women, after breast, colorectal and lung cancer. Despite intensive research, EC aetiology remains unknown. The variability, perceived in DNA repair genes, may be of clinical importance for evaluation of the risk of occurrence of a given type of cancer, its prophylactics and therapy. The aim of the study was to determine the relationship between gene polymorphism R156R (C to A, rs238406) of ERCC2 gene and modulation of the risk of endometrial cancer in Poland. Our research included 1360 patients with EC and 1320 healthy controls. The genotype analysis of ERCC2 gene polymorphism was performed using the PCR-based restriction fragment length polymorphism (PCR-RFLP). In the presented study, a relationship was identified between R156R polymorphism of the ERCC2 gene and the incidence of endometrial cancer. An association was observed between EC occurrence and the presence of A/A genotype (odds ratio (OR) 9.71, 95 % Cl 7.53–12.50, p < .0001). A tendency for an increased risk of endometrial cancer was detected with the occurrence of A allele of ERCC2 polymorphism (OR = 5.95, 95 % Cl 5.23–6.78, p < .0001). A relationship was confirmed between R156R polymorphism and endometrial cancer progression, assessed by histological grades. On the basis of these results, we conclude that ERCC2 gene polymorphism R156R may be associated with an increased risk of endometrial cancer.

Keywords

Endometrial cancer ERCC2 Polymorphism 

Notes

Conflicts of interest

None

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Wojciechowska U, Didkowska J, Zatoński W. Corpus uteri cancer. In: Zatoński W, editor. Cancer in Poland in 2006. Warsaw: Department of Epidemiology and Cancer Prevention; 2008. p. 30–2.Google Scholar
  3. 3.
    Hanawalt PC. Subpathways of nucleotide excision repair and their regulation. Oncogene. 2002;21:8949–56.CrossRefPubMedGoogle Scholar
  4. 4.
    Fan L, Fuss JO, Cheng QJ, Arvai AS, Hammel M, Roberts VA, et al. XPD helicase structures and activities: insights into the cancer and aging phenotypes from XPD mutations. Cell. 2008;133:789–800.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hui L, Yue S, Gao G, Chang H, Li X. Association of single-nucleotide polymorphisms in ERCC1 and ERCC2 with glioma risk. Tumour Biol. 2014;35:7451–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Tan X, Xian L, Chen X, Shi L, Wang Y, Guo J, et al. Association between ERCC2 Lys751Gln polymorphism and lung cancer risk: a meta-analysis involving 23,370 subjects. Twin Res Hum Genet. 2014;17:99–107.CrossRefPubMedGoogle Scholar
  7. 7.
    Ni M, Zhang WZ, Qiu JR, Liu F, Li M, Zhang YJ, et al. Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population. Sci Rep. 2014;4:4112.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Smolarz B, Makowska M, Samulak D, Michalska MM, Mojs E, Wilczak M, et al. Single nucleotide polymorphisms (SNPs) of ERCC2, hOGG1, and XRCC1 DNA repair genes and the risk of triple-negative breast cancer in Polish women. Tumour Biol. 2014;35:3495–502.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yin J, Vogel U, Ma Y, Guo L, Wang H, Qi R. Polymorphism of the DNA repair gene ERCC2 Lys751Gln and risk of lung cancer in a northeastern Chinese population. Cancer Genet Cytogenet. 2006;169:27–32.CrossRefPubMedGoogle Scholar
  10. 10.
    Ruyck K, Szaumkessel M, Rudder I, Dehoorne A, Vral A, Claes K, et al. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res. 2007;631:101–10.CrossRefPubMedGoogle Scholar
  11. 11.
    Brewster AM, Jorgensen TJ, Ruczinski I, Huang HY, Hoffman S, Thuita L, et al. Polymorphisms of the DNA repair genes ERCC2 (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer. Breast Cancer Res Treat. 2006;95:73–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhang Y, Wang L, Wang P, Song C, Wang K, Zhang J, et al. Association of single nucleotide polymorphisms in ERCC2 gene and their haplotypes with esophageal squamous cell carcinoma. Tumour Biol. 2014;35:4225–31.CrossRefPubMedGoogle Scholar
  13. 13.
    Wu KG, He XF, Li YH, Xie WB. Huang X Association between the XPD/ERCC2 Lys751Gln polymorphism and risk of cancer: evidence from 224 case-control studies. Tumour Biol. 2014;35:11243–59.CrossRefPubMedGoogle Scholar
  14. 14.
    Sobczuk A, Poplawski T, Blasiak J. Polymorphisms of DNA repair genes in endometrial cancer. Pathol Oncol Res. 2012;18:1015–20.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Vogel U, Dybdahl M, Frentz G, Nexo BA. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res. 2000;461:197–210.Google Scholar
  16. 16.
    Wolfe KJ, Wickliffe JK, Hill CE, Paolini M, Ammenheuser MM, Abdel-Rahman SZ. Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genomics. 2007;17:897–905.CrossRefPubMedGoogle Scholar
  17. 17.
    Hosseini M, Houshmand M, Ebrahimi A. The ERCC2 K751 polymorphism is associated with breast cancer risk. Arch Med Sci. 2009;35:455–9.Google Scholar
  18. 18.
    Lee JM, Yang PW, Yang SY, Chuang TH, Tung EC, Chen JS, et al. Genetic variants in DNA repair predicts the survival of patients with esophageal cancer. Ann Surg. 2011;253:918–27.CrossRefPubMedGoogle Scholar
  19. 19.
    Caggana M, Kilgallen J, Conroy JM, Wiencke JK, Kelysey KT, Miike R, et al. Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev. 2001;10:355–60.PubMedGoogle Scholar
  20. 20.
    Wrensch M, Kelsey KT, Liu M, Miike R, Moghadassi M, Sison JD, et al. ERCC1 and ERCC2 polymorphisms and adult glioma. Neuro-Oncol. 2005;7:495–507.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther. 1993;57:237–57.CrossRefPubMedGoogle Scholar
  22. 22.
    Stern MC, Conway K, Li Y, Mistry K, Taylor JA. DNA repair gene polymorphisms and probability of TP53 mutation in bladder cancer. Mol Carcinog. 2006;45:715–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Applebaum KM, Karagas MR, Hunter DJ, Catalano PJ, Byler SH, Morris S, et al. Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire. Environ Health Perspect. 2007;115:1231–6.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Doherty JA, Weiss NS, Fish S, Fan W, Loomis MM, Sakoda LC, et al. Polymorphisms in nucleotide excision repair genes and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2011;20:1873–82.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Weiss JM, Weiss NS, Ulrich CM, Doherty JA, Chen C. Nucleotide excision repair genotype and the incidence of endometrial cancer: effect of other risk factors on the association. Gynecol Oncol. 2006;103:891–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Weiss JM, Weiss NS, Ulrich CM, Doherty JA, Voigt LF, Chen C. Interindividual variation in nucleotide excision repair genes and risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2524–30.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Magdalena M. Michalska
    • 1
  • Dariusz Samulak
    • 1
    • 2
  • Filip Jabłoński
    • 3
  • Hanna Romanowicz
    • 3
  • Beata Smolarz
    • 3
  1. 1.Department of Obstetrics and GynaecologyRegional Hospital in KaliszKaliszPoland
  2. 2.Cathedral of Mother’s and Child’s HealthPoznań University of Medical SciencesPoznańPoland
  3. 3.Laboratory of Cancer Genetics, Department of PathologyInstitute of Polish Mother’s Memorial HospitalLodzPoland

Personalised recommendations